Femasys Secures First Blended Polymer Patents for FemBloc, Expanding Global IP Protection
FEMY is trading near its 52-week low of $2.291 (11% above the low) on elevated volume (2.5× avg).
Summary
Femasys has been granted the first patents covering the blended polymer component of its FemBloc non-surgical permanent birth control technology in the U.S., Japan, South Korea, Brazil, Hong Kong, India, and multiple European countries. These patents complement existing delivery system IP, extending protection into key global markets. The news follows a recent $30M private placement at a premium and insider purchases, reinforcing the company's momentum as it advances FemBloc through the U.S. pivotal trial. Strengthening the patent portfolio reduces competitive risk for a product already approved in Europe and other international markets, with U.S. FDA approval as the next major catalyst.
At the time of this announcement, FEMY was trading at $2.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $2.29 to $22.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.